Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae

不可分型流感嗜血杆菌脂质修饰蛋白候选疫苗的增强免疫原性和保护性研究

基本信息

  • 批准号:
    10042550
  • 负责人:
  • 金额:
    $ 24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-21 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Abstract: In the conjugate vaccine era, Nontypeable Haemophilus influenzae (NTHi) has become the leading cause of acute otitis media (AOM), recurrent AOM, acute sinusitis and conjunctivitis in children and adults and acute exacerbations of chronic obstructive pulmonary disease (COPD) in adults. There is need to develop a vaccine against NTHi. Various vaccine candidates have been explored but still there is need for enhancement of antibody and Th17 immunity response for NTHi vaccines that will help prevent nasopharyngeal colonization and infection. In this project we will compare immunogenicity of recombinant proteins P6 and OMP26 and their fusion constructs in their lipidated and non-lipidated form in a mouse coinfection model of NTHi-AOM, we developed. Two proteins were selected based on their different function and considering P6 is naturally lipidated and native OMP26 is not but is known to induce Th17 immunity. We will test our hypothesis that lipidated protein antigens elicit higher blood and mucosal antibody levels as well as Th17 immune response (via toll-like receptor 2 activation) than non lipidated proteins. Lipidated protein antigens will elicit greater reduction in ear and nasal bacterial loads compared to nonlipidated antigens against NTHi. The contribution and mechanism of antibody mediated and TH17-mediated immunity in protection against NTHi will be compared in infant and adult mice as well as in TLR2-knock out mice using lipidated, nonlipidated and fusion constructs of vaccine candidates P6 and OMP26. We will test whether lipidated proteins produce a more robust IL-17A response from memory Th17 cells in the nasopharynx that helps traffic neutrophils and show enhanced NTHi clearance compared to nonlipidated protein antigens. Overall, the proposed studies will significantly advance our understanding of enhanced immunogenicity of recombinant proteins and molecular mechanisms underlying the lipidation regulation of TLR-2 dependent Th17- immunity in NTHi vaccine development.
摘要: 在结合疫苗时代,不可分型流感嗜血杆菌(NTHi)已成为 急性中耳炎(AOM),复发性AOM,急性鼻窦炎和结膜炎的主要原因, 儿童和成人与慢性阻塞性肺疾病(COPD)急性加重 成年人了需要开发针对NTHi的疫苗。各种候选疫苗已经被 但是仍然需要增强NTHi的抗体和Th 17免疫应答 有助于预防鼻咽定植和感染的疫苗。在这个项目中,我们将 比较重组蛋白P6和OMP 26及其融合构建体在小鼠中的免疫原性。 在NTHi-AOM的小鼠共感染模型中,我们开发了它们的脂化和非脂化形式。 基于它们的不同功能选择两种蛋白质,并且考虑到P6是天然的。 脂化的和天然的OMP 26不诱导Th 17免疫,但已知其诱导Th 17免疫。我们将测试我们的 假设脂化蛋白抗原也引起更高的血液和粘膜抗体水平 Th 17免疫应答(通过Toll样受体2激活)。脂化 蛋白抗原将引起耳和鼻细菌负荷的更大减少, 抗NTHi的非脂化抗原。抗体介导的免疫反应的贡献和机制 将在婴儿和成年小鼠中比较TH 17介导的免疫对NTHi的保护作用, 以及在TLR 2敲除小鼠中使用脂质化、非脂质化和融合疫苗构建体 候选人P6和OMP 26。我们将测试脂化蛋白质是否产生更强的IL-17 A 来自鼻咽部记忆性Th 17细胞的反应,有助于中性粒细胞的运输, 与非脂化蛋白质抗原相比,NTHi清除增强。总体而言,拟议 这些研究将显著推进我们对重组免疫原性增强的理解, TLR-2依赖的脂化调节的蛋白质和分子机制 NTHi疫苗开发中的Th 17免疫。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ravinder Kaur其他文献

Ravinder Kaur的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ravinder Kaur', 18)}}的其他基金

Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzae
不可分型流感嗜血杆菌脂质修饰蛋白候选疫苗的增强免疫原性和保护性研究
  • 批准号:
    10245160
  • 财政年份:
    2020
  • 资助金额:
    $ 24万
  • 项目类别:
Antibody & Cellular Immune responses in children after 2 vs 3 doses and pre vs post booster of PCV13 Vaccine
抗体
  • 批准号:
    9316990
  • 财政年份:
    2017
  • 资助金额:
    $ 24万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 24万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了